Abstract. We surveyed the quality of life of adult patients with growth hormone (GH) deficiency, who ceased GH therapy before the age of 20. We sent quetionnaires to 1,116 patients and their physicians concerning their socio-economic status and medical background. Return rates were 64% and 69%, respectively.
Introduction
Growth hormone (GH) administration is the essential and most effective treatment in patients with GH deficiency. From 1974, we treated Japanese patients with GH prepared from the human pituitary gland at a low dosage of 0.2-0.4IU/kg/week.
The treatment ceased when the height reached 155cm in males and 150cm in females. This policy was maintained until recombinant GH preparations came on to the market in 1986 (1). We made a survey of the benefit of GH treatment to these patients in their life. This report summarises the results of our survey of 1,116 patients conducted from September, 1990 to March 1992.
Materials and Methods
The questionnaire to the patients referred to their present physical condition including height, weight, health problems, school and occupational career, socio-economic and marital status, and their evaluation and comments on the therapy.
The Cornell Medical Index (CMI) health questionnaire with modifications (2) was also used to assess their physical ofpatients had isolated GH deficiency (IGHD) and 65% GH deficiency with other pituitary hormone deficiency (multiple pituitary hormone deficiency: MPHD). Eighty-two percent of the patients received a dose of 0.2-0.4IU/ kg/week, which was considered to be less than the present therapeutic dose of 0.5IU/kg/ week. These figures indicate that the treatment in most of the patients was insufficient, and this was due to the shortage of human GH preparations. The results of the questionnaire need to be interpreted with this point in mind.
The age of the patients at the time of the survey ranged from 18 to 48 years, and 86% of them were in their 20s. The final height ranged from 120 to 180cm, and in both sexes 61% were above -2 standard deviation from the mean of the Japanese adult population: above 159cm in males and above 148cm in females. The mean of the final height for males was 157cm in IGHD and 162cm in MPHD (Fig. 1) ; that for females was 144cm in IGHD and 151cm in MPHD (Fig. 2) . Thus, in both sexes, the final height was much shorter in IGHD. This is probably due to the early onset of puberty in IGHD. These findings are similar to those reported previously (5,6,7). In 12% of the patients the end of their school career was junior high school, and this percentage is much higher than the national figure, which is about 4% (Fig. 3) . This was not because of their short stature, but most likely because of underlying diseases. The percentage of college graduates in the patients was lower than the national figure. The distributions of occupa- tion (Fig. 4 ) and income were quite similar to those in the general population. There was no association between height and annual income. Thirty-five percent of the patients changed employment, and this is close to the figure among the general population of the same age group. Among the male patients with final TAKANO et al. height below 155cm, 40% felt discrimination against short stature in finding jobs (Fig. 5) . Among the female patients with final height below 140cm this figure was 50%.
The number of patients who married was 30 for males and 32 for females, that is 6.0% and 17.2% respectively.
These percentages are lower than the those of the general population of the same age group (Fig. 6) . The percentage of patients with IGHD who married was 4 times more than in those with MPHD, in both sexes. Both groups of patients had children. Thirty-eight percent of the male and 22% of the female patients felt a disadvantage in finding marriage partners because of their short stature (Fig. 7) . Among single patients many expressed anxiety about sex in marriage, particularly MPHD male patients of short stature. Overweight, above 20% of the standard weight for height, was observed in 12% of male and 10% of female patients (Fig.  8) .
Eighty-three percent of patients ap- preciated the GH treatment. In particular, the males over 165cm and females over 150cm were satisfied with their present height (Fig.  9) . The main psychosocial problems were immature sexual development, anxiety about marriage, fatigue, overweight and inability to reach things. As far as GH treatment was concerned, they complained about the pain of injection but recommended others to start GH treatment as early as possible to achieve a good final height. CMI profiles (Fig. 10 ) indicated a significantly heigher rate of "yes" responses in sections J (presence of disease), M (maladjustment) and Q (anger) in male patients when compared with reference workers as controls (7.4% vs. 4.5%, 18.4% vs. 13.1%, 18.6% vs. 13.1%, respectively) . In female patients, a higher rate of "yes" responses was observed in sections J and K (past history of disease) (8.9% vs. 3.4%, 8.4% vs. 3.5%, respectively) . Neurotic tendency, as defined by Fukamachi (2), was observed in 11% of male patients with MPHD, which is vitality and increased anxiety, which led to a poor quality of life. They also reported that these clinical symptoms and signs improved dramatically with GH replacement therapy. Our study did not enter into the details of the quality of life of each patient. However, we came to the conclusion that most GHtreated adults in Japan adjusted themselves well to their psychosocial environment. There are, however, disadvantages for these patients in getting jobs or in finding marriage partners. We need further study to find out the best way to increase the final adult height, to ensure sexual development and finally to improve the quality of life of these patients.
